Clinically validated biomarkers including MSI, RAS and BRAF mutations, HER2 amplification, and CEA guide targeted therapy, while circulating tumor DNA and multi-omics profiling remain investigational with limited standardization. (Cells)
Review highlights expanding landscape of CRC biomarkers beyond RAS and BRAF
The CRC Digest